Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-109 nasal gel versus placebo in COVID-19
2021-000455-39Phase 2Completed
- Sponsor
- Pharma Holdings AS
- Start
- Feb 2021
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing LTX-109 nasal gel with Placebo gel (2 arms). Started Feb 2021; status: completed.
02
Drugs
voxvoganan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000455-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000455-39.